Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Should You Buy?

Key Points

• Telix Pharmaceuticals saw a significant increase in trading volume, with 108,908 shares traded, marking an 89% rise from the previous session.
• Analysts maintain a generally positive outlook on TLX, with a consensus rating of "Moderate Buy" and a target price averaging $22.33.
• Institutional investors actively invested in Telix Pharmaceutical, acquiring new positions worth substantial amounts in recent quarters.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 108,908 shares changed hands during mid-day trading, an increase of 89% from the previous session's volume of 57,587 shares.The stock last traded at $9.39 and had previously closed at $9.55.

Wall Street Analyst Weigh In

TLX has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush reissued an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, HC Wainwright started coverage on shares of Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $22.33.

Telix Pharmaceuticals Stock Down 0.2%

The business's 50 day moving average is $13.22 and its 200-day moving average is $15.77. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Pier Capital LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at $3,037,000. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at $975,000. Jane Street Group LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at $564,000. ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals in the 1st quarter valued at $451,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals in the 2nd quarter valued at $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.